GI
AKRO

GAMMA Investing’s Akero Therapeutics AKRO Stock Holding History

GAMMA Investing’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-369
Closed -$17.5K – 4069
2025
Q3 		$17.5K Sell
369
-67
-15% -$3.24K ﹤0.01% 2587
2025
Q2 		$23.3K Buy
436
+168
+63% +$7.63K ﹤0.01% 2378
2025
Q1 		$10.8K Buy
268
+135
+102% +$5.72K ﹤0.01% 2712
2024
Q4 		$3.7K Buy
133
+14
+12% +$424 ﹤0.01% 3028
2024
Q3 		$3.41K Buy
119
+76
+177% +$1.98K ﹤0.01% 2889
2024
Q2 		$1.01K Buy
43
+16
+59% +$342 ﹤0.01% 3057
2024
Q1 		$682 Buy
27
+14
+108% +$336 ﹤0.01% 3032
2023
Q4 		$281 Buy
+13
New +$256 ﹤0.01% 3085

Other funds holding AKRO

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

GAMMA Investing's AKRO Position: Q4 2025 in Review

GAMMA Investing sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 369 shares — an estimated $17.5K sold.

GAMMA Investing first reported a position in AKRO in Q4 2023 and held it in 8 quarters. The position peaked at $23.3K in Q2 2025. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.

  • GAMMA Investing reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
  • GAMMA Investing sold 369 Akero Therapeutics shares in Q4 2025, an estimated $17.5K.
  • GAMMA Investing first reported a position in Akero Therapeutics in Q4 2023 and held it in 8 quarters.
  • GAMMA Investing's Akero Therapeutics position peaked at $23.3K in Q2 2025.
  • 2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.

Based on GAMMA Investing's 13F filing for Q4 2025, filed 5 Jan 2026.